In what percentage of patients is molecular diagnostics now being performed? Is this level a cause for rejoicing, or should it be viewed as a challenge?
It is difficult to answer this question, because this percentage is small, but varies greatly regionally. This is evident from the report, according to which even large provinces such as Greater Poland are not in a good position.
Saving money on this research is a dead end, because nationwide and in terms of the effectiveness of treatment for many cancers, molecular testing opens up great possibilities. It used to be that diagnosis was very unsuccessful, and treatment was not very effective either. Today we have access to effective treatment, but its implementation must be preceded by a genetic test. If this test is not present, we have more losses than gains.
Patient organizations already established genetic diagnostics as a priority last year. This year we already have more support, and we will be telling the new authorities that this diagnostics in oncology means a lot. We already have a positive assessment from AOTMiT for ovarian cancer and lung cancer. We are waiting for a decision from the Ministry of Health. However, the process is dragging on.
The Genetic Testing Law is also in the hands of politicians. It talks about treatment standards and ensures patient safety in terms of sensitive data. There should be a central laboratory to store this data well and for a long time.
